Growth and safety Outcomes in infants with CMPA fed a novel extensively hydrolyzed formula.
Full-term infant(gestational age ≥37 weeks and ≤42 weeks).
Birth weight ≥2500 g and ≤4500 g.
Parent(s)/LAR deemed able to provide written informed consent for participation of their infant in the study (in the opinion of the investigator).
Participant aged ≥29 days (>4 weeks) and <5 months (≤22 weeks) at time of enrollment.
Prior use of eHF, HRF or AAF for more than 2 weeks before randomization.
Congenital illness or malformation that may affect growth, or significant pre-natal and/or serious post-natal disease other than CMPA before randomization (per investigator's medical decision).
Demonstrated chronic malabsorption not due to CMPA.
History of severe anaphylaxis to CMP.